| |
| |
|
| Insider
Information: |
Booth Mark D |
| Relationship: |
Chief Commercial Officer |
| City: |
La Jolla |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
3,810 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$20 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
3,810 |
|
|
| Total
Value |
$20 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Orexigen Therapeutics, Inc. |
OREX |
Chief Commercial Officer |
2015-02-26 |
3,810 |
2012-06-28 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
12 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| OREX |
Orexigen Therapeutics, In... |
Chief Commercial Officer |
• – – |
2015-02-26 |
4 |
AS |
$5.68 |
$284,200 |
D/D |
(50,000) |
3,810 |
0 |
- |
|
| OREX |
Orexigen Therapeutics, In... |
Chief Commercial Officer |
• – – |
2015-02-26 |
4 |
OE |
$1.66 |
$83,000 |
D/D |
50,000 |
53,810 |
0 |
- |
|
| OREX |
Orexigen Therapeutics, In... |
Chief Commercial Officer |
• – – |
2014-05-30 |
4 |
A |
$5.25 |
$22,145 |
D/D |
4,218 |
8,028 |
0 |
- |
|
| OREX |
Orexigen Therapeutics, In... |
Chief Commercial Officer |
• – – |
2013-11-29 |
4 |
A |
$5.34 |
$20,345 |
D/D |
3,810 |
3,810 |
0 |
- |
|
| OREX |
Orexigen Therapeutics, In... |
Chief Commercial Officer |
• – – |
2013-07-26 |
4 |
AS |
$7.25 |
$489,083 |
D/D |
(64,767) |
0 |
0 |
- |
|
| OREX |
Orexigen Therapeutics, In... |
Chief Commercial Officer |
• – – |
2013-07-26 |
4 |
OE |
$1.66 |
$107,513 |
D/D |
64,767 |
64,767 |
0 |
- |
|
| OREX |
Orexigen Therapeutics, In... |
Chief Commercial Officer |
• – – |
2013-03-11 |
4 |
AS |
$6.67 |
$184,659 |
D/D |
(27,685) |
0 |
0 |
- |
|
| OREX |
Orexigen Therapeutics, In... |
Chief Commercial Officer |
• – – |
2013-03-11 |
4 |
OE |
$1.66 |
$45,957 |
D/D |
27,685 |
27,685 |
0 |
- |
|
| OREX |
Orexigen Therapeutics, In... |
Chief Commercial Officer |
• – – |
2013-01-15 |
4 |
AS |
$6.67 |
$148,842 |
D/D |
(22,315) |
0 |
0 |
- |
|
| OREX |
Orexigen Therapeutics, In... |
Chief Commercial Officer |
• – – |
2013-01-15 |
4 |
OE |
$1.66 |
$37,043 |
D/D |
22,315 |
22,315 |
0 |
- |
|
| OREX |
Orexigen Therapeutics, In... |
Chief Commercial Officer |
• – – |
2012-06-28 |
4 |
AS |
$5.66 |
$584,729 |
D/D |
(103,309) |
0 |
0 |
- |
|
| OREX |
Orexigen Therapeutics, In... |
Chief Commercial Officer |
• – – |
2012-06-28 |
4 |
OE |
$1.66 |
$171,493 |
D/D |
103,309 |
103,309 |
0 |
- |
|
12 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
